Neoadjuvant nivolumab (N) plus /- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

被引：6
|
作者：
Guercio, Brendan John [1 ]
Pietzak, Eugene J. [1 ]
Brown, Samantha [1 ]
Chen, Jie-Fu [1 ]
Peters, Vanessa [1 ]
Regazzi, Ashley Marie [1 ]
Aggen, David Henry [1 ]
Donahue, Timothy F. [1 ]
Goh, Alvin C. [1 ]
Cha, Eugene K. [1 ]
Donat, S. Machele [1 ]
Dalbagni, Guido [1 ]
Bochner, Bernard H. [1 ]
Funt, Samuel Aaron [1 ]
Bajorin, Dean F. [1 ]
Iyer, Gopa [1 ]
Ostrovnaya, Irina [1 ]
Al-Ahmadie, Hikmat A. [1 ]
Rosenberg, Jonathan E. [1 ]
Teo, Min Yuen [1 ]
机构：
[1] US Natl Inst Health, Conquer Canc Fdn Amer Soc Clin Oncol, Bristol Myers Squibb, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.498
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
498
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
    Grivas, Petros
    Yin, Jun
    Koshkin, Vadim S.
    Cole, Suzanne
    Jain, Rohit K.
    Dreicer, Robert
    Cetnar, Jeremy Paul
    Sundi, Debasish
    Gartrell, Benjamin Adam
    Galsky, Matt D.
    Sievers, Colin M.
    Hahn, Noah M.
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Neoadjuvant nivolumab (N) plus ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).
    Teo, Min Yuen
    Guercio, Brendan John
    Pietzak, Eugene J.
    Ponomarev, Maria
    Regazzi, Ashley M.
    Quinlan, Colleen
    Aggen, David H.
    Donahue, Timothy F.
    Goh, Alvin C.
    Cha, Eugene K.
    Donat, S. Machele
    Dalbagni, Guido
    Bochner, Bernard H.
    Funt, Samuel A.
    Bajorin, Dean F.
    Iyer, Gopa
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat A.
    Coleman, Jonathan
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
    Yuxuan Song
    Tao Xu
    World Journal of Urology, 2023, 41 : 1697 - 1698
  • [4] Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
    Szabados, Bernadett
    Kockx, Mark
    Assaf, Zoe June
    van Dam, Pieter-Jan
    Rodriguez-Vida, Alejo
    Duran, Ignacio
    Crabb, Simon J.
    Van Der Heijden, Michiel S.
    Pous, Albert Font
    Gravis, Gwenaelle
    Herranz, Urbano Anido
    Protheroe, Andrew
    Ravaud, Alain
    Maillet, Denis
    Mendez, Maria Jose
    Suarez, Cristina
    Linch, Mark
    Prendergast, Aaron
    Tyson, Charlotte
    Stanoeva, Diana
    Daelemans, Sofie
    Rombouts, Miche
    Mariathasan, Sanjeev
    Tea, Joy S.
    Mousa, Kelly
    Sharma, Shruti
    Aleshin, Alexey
    Banchereau, Romain
    Castellano, Daniel
    Powles, Thomas
    EUROPEAN UROLOGY, 2022, 82 (02) : 212 - 222
  • [5] Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder
    Song, Yuxuan
    Xu, Tao
    WORLD JOURNAL OF UROLOGY, 2023, 41 (06) : 1697 - 1698
  • [6] Neoadjuvant nivolumab (N) plus ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
    Sternschuss, Michal
    Guercio, Brendan John
    Pietzak, Eugene J.
    Ponomarev, Maria
    Regazzi, Ashley M.
    Quinlan, Colleen
    Aggen, David H.
    Goh, Alvin C.
    Cha, Eugene K.
    Donat, S. Machele
    Hakimi, A. Ari
    Matulewicz, Richard
    Funt, Samuel A.
    Bajorin, Dean F.
    Iyer, Gopa
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat A.
    Rosenberg, Jonathan E.
    Coleman, Jonathan
    Teo, Min Yuen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 645 - 645
  • [7] Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.
    Rose, Kyle M.
    Bandini, Marco
    Huelster, Heather L.
    Basile, Giuseppe
    Naidu, Shreyas U.
    Spiess, Philippe E.
    Necchi, Andrea
    Li, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Can neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy improve survival in patients with cisplatin-ineligible muscle-invasive bladder cancer?
    Koie, Takuya
    Suzuki, Yuichiro
    Tobisawa, Yuki
    Yoneyama, Tohru
    Mori, Kazuyuki
    Okamoto, Akiko
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with FGFR overexpressing muscle-invasive bladder cancer.
    Yang, Yuanquan
    Jain, Rohit K.
    Gupta, Shilpa
    Tsung, Irene
    Gopalakrishnan, Dharmesh
    Gheeya, Jinesh S.
    Wei, Lai
    Satturwar, Swati
    Parwani, Anil
    Collier, Katharine A.
    Pohar, Kamal S.
    Sundi, Debasish
    Lee, Cheryl T.
    Li, Zihai
    Roychowdhury, Sameek
    Mortazavi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS899 - TPS899
  • [10] Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC)
    Li, Roger
    Spiess, Philippe E.
    Sexton, Wade J.
    Poch, Michael Adam
    Zemp, Logan
    Pow-Sang, Julio M.
    Zhang, Jingsong
    Dhillon, Jasreman
    Borjas, Gustavo
    Naidu, Shreyas U.
    Dorman, Denise
    Burke, James M.
    Mule, James J.
    Conejo-Garcia, Jose
    Jain, Rohit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345